BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trials for ischemic systolic heart failure. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. The company is also developing CardiALLO Cell Therapy System, an allogeneic off the shelf mesenchymal stem cell product candidate, which is in Phase II trials used for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system and Morph vascular access product line, which provides catheter products for interventional medicine. The company is based in San Carlos, California.